Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Cyclo Therapeutics, Inc. (CYTH)
Company Research
Source: Business Wire
Continued progress of pivotal Phase 3 study (TransportNPC™) evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) toward 48-week comparative interim analysis data readout, planned for Q1 2025Aligned development strategy for Trappsol® Cyclo™ with FDA to enable a patient population lacking available therapies to have earlier access to a potentially efficacious product with an acceptable safety profileEnded the year with approximately $9.2 million cash to fund operations; continued efforts to bolster cash position and extend runway through clinical and regulatory milestones GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.“We made sign
Show less
Read more
Impact Snapshot
Event Time:
CYTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTH alerts
High impacting Cyclo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CYTH
News
- Niemann-Pick Disease Type C Market Insight, Epidemiology and Market Forecast - 2032, Featuring Zevra Therapeutics, Azafaros, Cyclo Therapeutics and IntraBio [Yahoo! Finance]Yahoo! Finance
- Cyclo Therapeutics, Inc. (NASDAQ: CYTH) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $3.00 price target on the stock.MarketBeat
- Cyclo Therapeutics, Inc. (NASDAQ: CYTH) is now covered by analysts at Ascendiant Capital Markets. They set a "buy" rating and a $2.60 price target on the stock.MarketBeat
- Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
CYTH
Sec Filings
- 4/29/24 - Form 10-K/A
- 3/18/24 - Form 10-K
- 3/4/24 - Form 8-K/A
- CYTH's page on the SEC website